Literature DB >> 14561719

Variation in the divalent cation requirements of influenza a virus N2 neuraminidases.

Bert E Johansson1, Ian C Brett.   

Abstract

Influenza virus N2 neuraminidases were chromatographically purified from several vaccine candidate strains from 1957 to 1994. Enzymatic kinetic parameters and immunogenicity were tested for each strain. For each NA tested, with ionic strength held constant, Ca(2+) or Mg(2+) increased the initial rate of enzymatic activity. Earlier N2-NA strains had the highest initial velocity, V(max)/K(m) and V(max). There were significant differences among the influenza virus strains in enzymatic activity before and after addition of Ca(2+) or Mg(2+): V(max)/K(m) varied from 0.54 M(-1) s(-1) to 0.88 M(-1) s(-1) and V(max) varied from 2.45 s(-1) to 4.3 s(-1) before the addition of a divalent cation; and increased approximately 2-fold each of these kinetic parameters for each strain after the addition of exogenous Ca(2+) or Mg(2+). Exhaustive dialysis with EDTA reduced the initial velocity of each strain with significant differences found among strains, with a range of 0.1% to 8% of original activity. Activity was partially restored by the addition of exogenous Ca(2+) or Mg(2+), varying from 8% to 60% of pre-dialysis levels, but original rates were not achieved. This reduction in enzymatic activity for the tested strains (i.e., A/Japan/57 and A/Johannesburg/94) was accompanied by a parallel decrease in NA-immunogenicity, with antibody response decreasing by as much as 76% as measured by NI titer, and ELISA titer decreasing by as much as 68%. The addition of Ca(2+) or Mg(2+) to the post-dialysis sample restored immunogenicity to as much as 80% of pre-dialysis NI titers and as much as 78% of pre-dialysis ELISA titers. Dialysis had the least effect on early strains as measured by enzymatic kinetic parameters and immunogenicity studies. Zn(2+) had a slight inhibitory effect on the activity of all tested strains. Review of the nucleic acid sequence of each of these strains could not predict their enzymatic activity, immunogenicity or response to dialysis. If immunity against neuraminidase is desirable in vaccination against influenza, selection of vaccine candidate strains must include not only analysis of antigenic changes and sequence analysis but also enzymatic studies and determination of the requirement of divalent cations to maintain immunogenicity and activity during production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561719     DOI: 10.1093/jb/mvg151

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  5 in total

Review 1.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

2.  Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition.

Authors:  Paulina M Dominiak; Anatoliy Volkov; Adam P Dominiak; Katarzyna N Jarzembska; Philip Coppens
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-04-18

3.  Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.

Authors:  Tadanobu Takahashi; Chairul A Nidom; Mai Thi Quynh Le; Takashi Suzuki; Yoshihiro Kawaoka
Journal:  FEBS Open Bio       Date:  2012-09-05       Impact factor: 2.693

4.  The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine.

Authors:  Luca T Giurgea; Jae-Keun Park; Kathie-Anne Walters; Kelsey Scherler; Adriana Cervantes-Medina; Ashley Freeman; Luz Angela Rosas; John C Kash; Jeffery K Taubenberger; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2021-04-06       Impact factor: 7.344

5.  Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic.

Authors:  Tadanobu Takahashi; Jiasheng Song; Takashi Suzuki; Yoshihiro Kawaoka
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.